INT103328

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.44
First Reported 2002
Last Reported 2010
Negated 2
Speculated 2
Reported most in Body
Documents 9
Total Number 25
Disease Relevance 11.89
Pain Relevance 0.93

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (F8) oxidoreductase activity (F8) extracellular region (F8)
cell adhesion (F8) plasma membrane (F8)
Anatomy Link Frequency
plasma 8
platelets 3
mesenteric vein 1
portal vein 1
vein 1
F8 (Homo sapiens)
Pain Link Frequency Relevance Heat
abdominal pain 2 98.52 Very High Very High Very High
headache 4 97.28 Very High Very High Very High
cva 74 91.36 High High
Inflammation 20 77.80 Quite High
Pain 17 50.96 Quite High
corticosteroid 8 5.60 Low Low
cINOD 3 5.00 Very Low Very Low Very Low
Lasting pain 2 5.00 Very Low Very Low Very Low
vincristine 2 5.00 Very Low Very Low Very Low
tolerance 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Thrombosis 26 99.88 Very High Very High Very High
Disease 58 99.68 Very High Very High Very High
Graves' Ophthalmopathy 2 99.50 Very High Very High Very High
Coagulation Disorder 1093 99.48 Very High Very High Very High
Thrombosis Related Under Development 4 99.22 Very High Very High Very High
Abdominal Pain 2 98.52 Very High Very High Very High
Cv Unclassified Under Development 4 98.20 Very High Very High Very High
Hemorrhage 467 97.96 Very High Very High Very High
Injury 111 97.36 Very High Very High Very High
Headache 4 97.28 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The binding of PEGLip to FVIII and FVIIa was demonstrated in real time using surface plasmon resonance (SPR).
FVIII Binding (binding) of
1) Confidence 0.44 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 0 Pain Relevance 0
Due to their prior association with PEGLip, they carry FVIII and FVIIa with them.
FVIII Binding (association) of
2) Confidence 0.44 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 0.35 Pain Relevance 0
The PEG molecules that extend outward from the liposome surface mediate binding of FVIII, FVIIa and other proteins to the liposome surface (Figure 1).
FVIII Binding (binding) of
3) Confidence 0.44 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 0 Pain Relevance 0
This was demonstrated by binding of several anti-FVIII antibodies to FVIII following PEGLip formulation45 Moreover, PEGLip formulation allows FVIII to interact with its natural binding partners.
FVIII Binding (interact) of
4) Confidence 0.38 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 0 Pain Relevance 0
We found that non-PEGylated POPC liposomes do not bind FVIII,45,46 FVIIa,47 or the FVIII-derived synthetic peptide.48 Analyses performed with liposomes composed of various types of lipids and lipid polymers revealed that the interaction between PEGLip and proteins is mediated primarily by the PEG molecule and the carbamate group adjacent to the PEG molecule within DSPE-PEG 2000.48 When PEG molecules were not present on the liposome surface (as in the case of POPC liposomes) no binding occurred.
FVIII Neg (not) Spec (Analyses) Binding (bind) of
5) Confidence 0.38 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 0 Pain Relevance 0
According to recent recommendations, human plasma-derived or recombinant FVIII concentrates can be used in acquired hemophilia for the treatment of minor bleeding manifestations and acute bleeding episodes when the inhibitor titer is low (?
FVIII Binding (recombinant) of in plasma associated with coagulation disorder and hemorrhage
6) Confidence 0.37 Published 2010 Journal J Med Case Reports Section Body Doc Link PMC2918632 Disease Relevance 0.64 Pain Relevance 0
According to recent recommendations, human plasma-derived or recombinant FVIII concentrates can be used in acquired hemophilia for the treatment of minor bleeding manifestations and acute bleeding episodes when the inhibitor titer is low (?
FVIII Binding (recommendations) of in plasma associated with coagulation disorder and hemorrhage
7) Confidence 0.37 Published 2010 Journal J Med Case Reports Section Body Doc Link PMC2918632 Disease Relevance 0.65 Pain Relevance 0
According to recent recommendations, human plasma-derived or recombinant FVIII concentrates can be used in acquired hemophilia for the treatment of minor bleeding manifestations and acute bleeding episodes when the inhibitor titer is low (?
FVIII Binding (used) of in plasma associated with coagulation disorder and hemorrhage
8) Confidence 0.37 Published 2010 Journal J Med Case Reports Section Body Doc Link PMC2918632 Disease Relevance 0.65 Pain Relevance 0
The diagnosis of acquired hemophilia is based on the demonstration of an isolated prolongation of the activated partial thromboplastin time, not corrected by incubating the patient’s plasma with equal volumes of normal plasma (mixing study), associated with low factor VIII levels and evidence of a factor VIII inhibitor (which can be titrated in Bethesda units (BU)/mL), in a patient with no previous personal or family history of bleeding (Cohen and Kessler 1996).
factor VIII Binding (associated) of in plasma associated with coagulation disorder and hemorrhage
9) Confidence 0.35 Published 2007 Journal Clinical Interventions in Aging Section Body Doc Link PMC2685275 Disease Relevance 1.30 Pain Relevance 0.09
The diagnosis of acquired hemophilia is based on the demonstration of an isolated prolongation of the activated partial thromboplastin time, not corrected by incubating the patient’s plasma with equal volumes of normal plasma (mixing study), associated with low factor VIII levels and evidence of a factor VIII inhibitor (which can be titrated in Bethesda units (BU)/mL), in a patient with no previous personal or family history of bleeding (Cohen and Kessler 1996).
factor VIII Binding (associated) of in plasma associated with coagulation disorder and hemorrhage
10) Confidence 0.35 Published 2007 Journal Clinical Interventions in Aging Section Body Doc Link PMC2685275 Disease Relevance 1.31 Pain Relevance 0.09
The FVIII used to treat hemophilia A may be produced in mammalian cell lines genetically engineered to synthesize human FVIII (recombinant FVIII, rFVIII) or may be purified from normal pooled plasma (plasma-derived FVIII, pdFVIII).8
rFVIII Binding (recombinant) of in plasma associated with coagulation disorder
11) Confidence 0.34 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 1.01 Pain Relevance 0.12
The combined results indicate the following mechanism (Figure 4): Formulation of FVIII or FVIIa with PEGLip leads to non-covalent binding of the protein to the outer surface of the PEGylated liposomes.
FVIII Binding (binding) of
12) Confidence 0.34 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 0.22 Pain Relevance 0
The association of PEGLip-FVIII or PEGLip-FVIIa with platelets may also lead to increased concentration of FVIII or FVIIa at the wound site, even when the overall concentration of FVIII or FVIIa in the circulation is low.
PEGLip-FVIII Binding (association) of in platelets associated with injury
13) Confidence 0.34 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 0.48 Pain Relevance 0
Mice that received PEGLip-FVIII bled less and survived significantly longer (P < 0.05) than mice that received standard FVIII or saline (Figure 2A).45,46 This significantly increased survival of tail-vein transected hemophilic mice following the injection of PEGip formulated recombinant FVIII was also demonstrated by others.50 The increased survival rate was dependent on the pre-formation of a complex of FVIII and PEGLip.
FVIII Binding (complex) of in vein
14) Confidence 0.34 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 0.34 Pain Relevance 0
This was shown by in-vitro binding of PEGLip-formulated FVIII to vWF.45 Thus binding of PEGLip to FVIII does not change the protein’s biological properties.
FVIII Binding (binding) of
15) Confidence 0.33 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 0 Pain Relevance 0
Fluorescently labeled FVIII and FVIIa were formulated with non-fluorescent PEGLip and shown by flow cytometry to bind human platelets in-vitro.
FVIII Binding (bind) of in platelets
16) Confidence 0.33 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 0.06 Pain Relevance 0
FVIII binds PEGLip specifically and with high affinity (two binding sites, KD of 4.5 and 1.9 nM), but this interaction does not alter FVIII activity, as shown by maintenance of full activity after formulation.45,46 The association of FVIII with PEGLip does not affect the FVIII protein’s structure.
FVIII Binding (binds) of
17) Confidence 0.33 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 0 Pain Relevance 0
Having shown that PEGLip bind FVIII and FVIIa45,47 and that PEGLip bind platelets, we next tested whether PEGLip are capable of delivering proteins to platelets.
FVIII Binding (bind) of in platelets
18) Confidence 0.33 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 0.07 Pain Relevance 0
The FVIII used to treat hemophilia A may be produced in mammalian cell lines genetically engineered to synthesize human FVIII (recombinant FVIII, rFVIII) or may be purified from normal pooled plasma (plasma-derived FVIII, pdFVIII).8
pdFVIII Binding (plasma) of in plasma associated with coagulation disorder
19) Confidence 0.30 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 0.88 Pain Relevance 0.04
A synthetic peptide derived from one of the two consensus sequences in FVIII (amino acids 1783–1796 of FVIII) also binds PEGLip with high affinity (KD of 2.3 nM).
FVIII Binding (binds) of
20) Confidence 0.30 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox